Payload Information
General Information of This Payload
| Payload ID | PAY0ZPJTZ |
|||||
|---|---|---|---|---|---|---|
| Name | WO2023221971A1 NEC49-4 Payload |
|||||
| Synonyms |
WO2023221971A1 NEC49-4 Payload
Click to Show/Hide
|
|||||
| Structure |
|
|||||
| Formula | C29H28FN3O6 |
|||||
| Isosmiles | O[C@@H](C(N[C@H]1CCC(C(C)=C(F)C=C2N=C3C4=CC([C@@]5(O)CC)=C6COC5=O)=C2C1=C3CN4C6=O)=O)C7CC7 |
|||||
| InChI |
InChI=1S/C29H28FN3O6/c1-3-29(38)17-8-21-24-15(10-33(21)27(36)16(17)11-39-28(29)37)23-19(32-26(35)25(34)13-4-5-13)7-6-14-12(2)18(30)9-20(31-24)22(14)23/h8-9,13,19,25,34,38H,3-7,10-11H2,1-2H3,(H,32,35)/t19-,25+,29-/m0/s1
|
|||||
| InChIKey |
ODYAHADGPIHDQN-CIKSPIGKSA-N
|
|||||
| Pharmaceutical Properties | Molecule Weight |
533.556 |
Polar area |
130.75 |
||
Complexity |
1648.255577 |
xlogp Value |
2.40152 |
|||
Heavy Count |
39 |
Rot Bonds |
4 |
|||
Hbond acc |
8 |
Hbond Donor |
3 |
|||
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
Trastuzumab-C-22 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.053 nM
|
High HER2 expression (HER19 +++) | ||
| Method Description |
Trastuzumab-C-21 was tested in HCC1954,80ul,18ᆬh
|
||||
| In Vitro Model | Breast ductal carcinoma | HCC1954 cells | CVCL_1259 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.103 nM
|
High HER2 expression (HER19 +++) | ||
| Method Description |
Trastuzumab-C-21 was tested in NCI-N87,80ul,18ᆬh
|
||||
| In Vitro Model | Gastric tubular adenocarcinoma | NCI-N87 cells | CVCL_1603 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
14.05 nM
|
High HER2 expression (HER19 +++) | ||
| Method Description |
Trastuzumab-C-21 was tested in HCC1954 and PBMC,50ul,24h
|
||||
| In Vitro Model | Breast ductal carcinoma | HCC1954 cells | CVCL_1259 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Emax (TNF-a) |
1562.5 pg/mL
|
High HER2 expression (HER19 +++) | ||
| Method Description |
Trastuzumab-C-21 was tested in HCC1954 and PBMC,50ul,24h
|
||||
| In Vitro Model | Breast ductal carcinoma | HCC1954 cells | CVCL_1259 | ||
NEC49-9-A [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.0798 nM
|
High Nectin-4 expression (Nectin-4 +++) | ||
| Method Description |
Ab4 ADC was tested in T24 mScarlet clone 5 nectin-4 negative cells ;and with a DAR of 8
|
||||
| In Vitro Model | Bladder carcinoma | T24 mScarlet clone 5 nectin-4 negative cells | CVCL_0554 | ||
References